ReviewWorld journal of pediatrics : WJP2020
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
Review in World journal of pediatrics : WJP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Global landscape of juvenile dermatomyositis research: a bibliometric analysis.Pediatric research · 2026Article
- Comprehensive Analysis Reveals Potential Molecular Targets in Juvenile Dermatomyositis.Biochemistry research international · 2026Article
- Neutrophil activation in juvenile dermatomyositis: associations with muscle function and disease progression.Pediatric rheumatology online journal · 2025Article
- Nailfold videocapillaroscopy in juvenile dermatomyositis: detailed correlations between microvascular abnormalities with clinical and laboratory parameters from an observational retrospective single-center study.Clinical rheumatology · 2025Observational
- Expert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Tofacitinib: a promising agent for the treatment of persistent rashes in juvenile dermatomyositis.World journal of pediatrics : WJP · 2025Article
- Perspectives and experiences of parents of children with juvenile dermatomyositis: a semi-structured interview study.Pediatric rheumatology online journal · 2025Article
- Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies.Paediatric drugs · 2025Review
- The Role of Pyroptosis-Related Gene Signature and Immune Infiltration in Juvenile Dermatomyositis.Clinical, cosmetic and investigational dermatology · 2025Article
- Therapeutic plasma exchange in autoimmune diseases: a retrospective study in a tertiary pediatric hospital in Mexico.Frontiers in pediatrics · 2025Article
- Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.Expert opinion on pharmacotherapy · 2024Review
- Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.Expert review of clinical immunology · 2024Review
- A less common case of anti-MDA5 and anti-Ro52 antibody-positive juvenile dermatomyositis complicated with macrophage activation syndrome.Clinical case reports · 2024Article
- Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis.Rheumatology (Oxford, England) · 2024Article
- Deep RNA sequencing of muscle tissue reveals absence of viral signatures in dermatomyositis.Free neuropathology · 2024Article
- Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances.Reumatologia · 2024Article
- Anti-nuclear matrix protein 2 antibody-associated juvenile dermatomyositis with gastrointestinal perforations was successfully treated with traditional therapeutic drugs combined with vedolizumab: a case report after a long-term follow-up and a review of the literature.Frontiers in pediatrics · 2024Article
- Juvenile Dermatomyositis During the SARS-CoV-2 Pandemic: Acral and Oral Mucosal Involvement.Actas dermo-sifiliograficas · 2023Article
- Juvenile dermatomyositis and nephrotic syndrome: A case report and a mini literature review.Frontiers in pediatrics · 2023Article
- Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study.Northern clinics of Istanbul · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJuvenile dermatomyositis (JDM) is a chronic autoimmune disease characteristic by inflammation of small vessels within the skin, muscle and vital organs. But the clinical features and treatment of JDM have not been fully clarified. DATA SOURCES: Databases underwent through PubMed for articles about the clinical features, myositis-specific antibodies of JDM and its treatment, and we selected publications written in English which were relevant to the topic of this review.
resultsClinical features and myositis-specific antibodies may predict the severity and prognosis of disease. Although the mortality rate has been lower with traditional treatments, such as corticosteroid, intravenous immunoglobulin, and disease-modifying anti-rheumatic drugs such as methotrexate, their usages are variable. Novel biological therapies seem to be effective for refractory JDM patients, but more clinical trials are necessary.
conclusionsJDM is a sever disease of childhood. We need to better understand recent advances of JDM in the context of clinical features including skin manifestations, muscle weakness and organ damage, myositis-specific antibodies and their associated outcomes and the treatment of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.